NCT04068831 2024-12-27Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaMemorial Sloan Kettering Cancer CenterPhase 2 Completed18 enrolled 9 charts
NCT03875313 2022-02-17Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsCalithera Biosciences, IncPhase 1/2 Terminated33 enrolled 14 charts